Lucid announces investigators awarded $8M grant to investigate EsoCheck

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that a consortium of prestigious academic medical centers, led by principal investigators from Case Western Reserve University and University Hospitals, has been awarded an $8 million National Institutes of Health, NIH, R01 grant to conduct a five-year clinical study designed to evaluate esophageal precancer detection using Lucid’s EsoCheck Esophageal Cell Collection Device and EsoGuard Esophageal DNA Test among at-risk individuals without symptoms of chronic gastroesophageal reflux disease.